Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer

Exclusion Criteria

• •1. Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) requiring oxygen)
• •2. Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity®)
• •3. Right to left shunt, severe pulmonary hypertension (Pulmonary artery pressure \>90mmHg), or adult respiratory distress syndrome
• •4. Active cardiac disease including any of the following:
• •* Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association)
• •* Unstable angina.
• •* Severe arrhythmia (i.e. ventricular tachycardia, flutter fibrillation; ventricular premature complexes occurring close to the preceding T-wave, multifocal complexes).
• •* Myocardial infarction within 14 days prior to the date of proposed Definity® administration.
• •* Uncontrolled systemic hypertension (Blood pressure: systolic blood pressure (BP) \>150 mm Hg and/or diastolic BP \>90 mm Hg despite optimal medical management not controllable by medication to achieve BP \<15/90)
• •5. Is in an intensive care setting
• •6. Has an unstable neurological disease (e.g recent stroke or TIA symptoms (\<3 months)) cerebrovascular accident (including transient ischemic attacks (TIAs) within the 3 months before signing of informed consent
• •7. Undergone an invasive procedure on kidney lesion (e.g. tissue biopsy, surgery, nonsurgical cytoreductive procedure) in-between identification of lesion via US without contrast and perflutren lipid administration
• •8. Has previously been entered into this study or has received an investigational drug within the 30 days prior to admission into this study
• •9. Has any other medical condition or other circumstances that would significantly decrease the chances of obtaining reliable data or of achieving the study objectives such as:
• •* Mental illness
• •* Drug abuse
• •10. Female patient who is pregnant or lactating (the possibility of pregnancy has to be excluded by negative serum or urine B-HCG results, obtained within 24 hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses).